Trials / Completed
CompletedNCT02835742
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Niigata University Medical & Dental Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Objective: Determine the safety and efficacy of GM-CSF inhalation in patients with aPAP. Study Design: multi-center, randomized, double-blind, placebo- controlled, safety/efficacy study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sargramostim | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-08-01
- Completion
- 2018-06-01
- First posted
- 2016-07-18
- Last updated
- 2019-02-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02835742. Inclusion in this directory is not an endorsement.